Associate
Complex Commercial Litigation
Alex represents clients in both civil and criminal matters, with a particular focus on antitrust disputes and government investigations. He has worked with companies and individuals across a broad range of industries such as tech, energy, chemicals, and finance. A key part of Alex’s practice involves representing clients in connection with enforcement actions and related lawsuits brought by various government authorities, including the Department of Justice, United States’ Attorneys Offices, the Federal Trade Commission, state Attorney General offices, and others. He also represents clients in large class action lawsuits and in connection with proceedings before foreign regulatory authorities. Alex’s experience in these high-stakes matters makes him adept at navigating complex legal landscapes to protect the interests of his clients.
The following is a list of representative matters in which Alex has assisted.
Represents leading US technology company in domestic and foreign conduct investigations by competition regulators
Representing national property management company in connection with a series of consolidated class actions alleging the existence of a conspiracy to increase or stabilize the price of apartments using a common algorithm
Representing multinational financial services company in lawsuit brought by 11 state attorneys general concerning alleged conspiracy to cut coal production
Representing a large corporate entity in connection with Department of Justice False Claims Act investigation
Representing former employees of publicly traded company in connection with Department of Justice money laundering investigation
Counsels leading US technology company on competition related issues of potential acquisitions, interoperability, artificial intelligence, ecosystems, and emerging technology
Represented major retailer in internal investigation and government investigations related to sustainability and human capital initiatives and policies
Represented high-profile former government official before a congressional committee and the Department of Justice
Represented several large U.S. companies in connection with grand jury proceedings and as third parties in litigation
Represented Reata Pharmaceuticals in its $7 billion sale to Biogen
Represented Denbury Inc., a provider of CO2 pipelines and carbon capture services, in its $4.9 billion acquisition by Exxon Mobil Corp.
Represented Sunoco in the $1 billion sale of 204 convenience stores to 7-Eleven
Education
Admissions
Client Alerts
Parties to transactions should be aware of new requirements for state-level merger reporting – so-called “mini-HSR Acts” – modeled on the Uniform Antitrust Pre-Merger Notification Act (“UAPNA”).
July 28, 2025 • V&E Antitrust Update
July 28, 2025 • 5-minute read
Client Alerts
First 100 Days of the New HSR Rules
One hundred days ago, sweeping revisions to the Hart-Scott-Rodino Act Premerger Notification Form took effect.
May 21, 2025 • V&E Antitrust Update
May 21, 2025 • 6-minute read
Client Alerts
The New Administration: Trends in Antitrust Enforcement
The Trump Administration’s antitrust enforcement priorities are beginning to take shape. On January 20, 2025, President Trump designated former Federal Trade Commission (FTC) commissioner Andrew Ferguson as the agency’s next Chair and formally nominated Mark Meador, an FTC veteran, to be a Commissioner. In addition, Trump nominated Gail Slater to be the next head of the Justice Department’s Antitrust Division.
January 22, 2025
January 22, 2025 • 6-minute read
Client Alerts
The Federal Trade Commission (“FTC”) has revised the thresholds that govern pre-merger notification requirements under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR Act”), and Section 8 of the Clayton Act governing “interlocking directorates.”
January 13, 2025 • V&E Antitrust Update
January 13, 2025 • 6-minute read
Client Alerts
Business Groups Sue to Block Enforcement of New HSR Rule
On Friday, January 10, 2025, the Chamber of Commerce, Business Roundtable, American Investment Council, and Longview Chamber of Commerce filed a complaint in the Eastern District of Texas against the Federal Trade Commission (“FTC”) and its Chair Lina Khan to block the enforcement of the FTC’s new rule expanding the scope of the Hart-Scott-Rodino Act Premerger Notification Form (the “new HSR Rule”) set to take effect on February 10, 2025.
January 13, 2025 • V&E Antitrust Update
January 13, 2025 • 3-minute read
Deals & Cases
Vinson & Elkins advised Black Mountain Sand LLC, a Texas-based in-basin frac sand provider, in connection with the closing of its definitive agreement to merge in an all-stock transaction with Covia Energy LLC.
November 5, 2024
November 5, 2024 • 1-minute read
Deals & Cases
Vinson & Elkins advised Trace Midstream Partners II, LLC (Trace), a portfolio company of Quantum Capital Group (“Quantum”), in its entry into agreements with LM Energy Delaware, LLC (“LM Energy”), a portfolio company of Old Ironsides Energy, LLC (“Old Ironsides Energy”), to acquire its natural gas gathering and transportation assets in the Northern Delaware Basin.
August 6, 2024
August 6, 2024 • 1-minute read
Deals & Cases
JPI to be Acquired by Sumitomo Forestry America, Inc.
Vinson & Elkins advised Sumitomo Forestry America, Inc., a comprehensive housing and wood products subsidiary of Sumitomo Forestry Co., Ltd., in the acquisition of JPI’s operating platform.
October 2, 2023
October 2, 2023 • 1-minute read
Deals & Cases
HF Sinclair Corporation and Holly Energy Partners, L.P. Announce Definitive Merger Agreement
Vinson & Elkins advised HF Sinclair Corporation (“HF Sinclair”) on its entry into a definitive agreement to acquire all of the outstanding common units of Holly Energy Partners, L.P. (“HEP”) not owned by HF Sinclair or its affiliates in exchange for a combination of 0.315 shares of HF Sinclair common stock and $4.00 in cash for each publicly held HEP common unit.
August 16, 2023
August 16, 2023 • 1-minute read
Deals & Cases
Biogen to Acquire Reata Pharmaceuticals
Vinson & Elkins advised Reata Pharmaceuticals Inc. (“Reata”), a global biopharmaceutical company committed to developing and commercializing novel therapeutics for patients with serious or life-threatening diseases, in its entry into a definitive agreement under which Biogen Inc. has agreed to acquire Reata for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion.
July 28, 2023
July 28, 2023 • 1-minute read
our People
Please note that any communication with Vinson & Elkins via e-mail through this website does not constitute or create an attorney-client relationship with V&E. Please do not send any confidential information. A conflicts-of-interest procedure must be completed by V&E prior to establishment of an attorney-client relationship. When you execute an engagement letter from V&E you will be our client, and you may then exchange information freely with a V&E attorney.
By clicking “Accept,” you agree that we may review any information you transmit to us. You recognize that our review of your information, even if it is highly confidential and even if it is transmitted in a good faith effort to retain us, does not preclude us from representing another client directly adverse to you, even in a matter where that information could and will be used against you.
